Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human MAGEA3 Antibody (SAA1562)

Catalog #:   RHE41801 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, FCM
Accession: P43357
Overview

Catalog No.

RHE41801

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

Antigen MZ2-D, MAGE3, Melanoma-associated antigen 3, CT1.3, MAGE-3 antigen, Cancer/testis antigen 1.3, MAGEA3

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P43357

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1562

Data Image
References

De novo functional discovery of peptide-MHC restricted CARs from recombinase-constructed large-diversity monoclonal T cell libraries., PMID:39651191

Revealing molecular and cellular heterogeneity in hypopharyngeal carcinogenesis through single-cell RNA and TCR/BCR sequencing., PMID:38720887

Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma., PMID:37866309

Successful targeting in situ of an oncogenic nuclear antigen by hapten induced tumor associated autoantibodies (iTAA)., PMID:37336938

Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients., PMID:36527482

Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity., PMID:35987136

Generalizable design parameters for soluble T cell receptor-based T cell engagers., PMID:35260435

The expression of multiple cancer/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients., PMID:34462402

MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation., PMID:33227008

Differential Expression of Cancer Testis Antigens on Lentigo Maligna and Lentigo Maligna Melanoma., PMID:32701706

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma., PMID:32114500

Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status., PMID:31407331

The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis., PMID:31093793

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials., PMID:30546947

Intramuscular Immunization Induces Antigen-specific Antibodies in Urine., PMID:30219710

Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins., PMID:30186454

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic., PMID:30094070

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial., PMID:29908991

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature., PMID:29177094

Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab., PMID:28951518

An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide., PMID:28910565

The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions., PMID:28768706

Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg., PMID:28641561

Correlation Between Expression of the Cancer/Testis Antigen KK-LC-1 and Helicobacter pylori Infection in Gastric Cancer., PMID:28438869

MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy., PMID:28146422

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting., PMID:27563655

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial., PMID:27132212

L-Rhamnose Enhances the Immunogenicity of Melanoma-Associated Antigen A3 for Stimulating Antitumor Immune Responses., PMID:26978574

Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination., PMID:26888315

Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells., PMID:26702740

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer., PMID:26309191

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients., PMID:25944688

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention., PMID:25870800

Targeting the immune system to treat lung cancer: rationale and clinical experience., PMID:25827132

Immunotherapy in lung cancer., PMID:25806276

Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells., PMID:25704851

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)., PMID:25537079

Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment., PMID:25530039

Immunotherapy and lung cancer: current developments and novel targeted therapies., PMID:25496336

Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys., PMID:25219328

Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer., PMID:25101620

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation., PMID:25078248

MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells., PMID:25031712

Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines., PMID:25030654

Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient., PMID:24991188

Update on vaccines for high-risk melanoma., PMID:24788575

Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer., PMID:24675493

MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine., PMID:24671426

[Advances in immunotherapies for non-small cell lung cancer]., PMID:24667269

Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy., PMID:24614036

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human MAGEA3 Antibody (SAA1562) [RHE41801]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only